In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Diagnostics Gets Rolling

Executive Summary

Bayer AG's purchase of Chiron Diagnostics for $1.1 billion in cash demonstrates its commitment to diagnostics and also indicates Chiron Corp.'s negotiating savvy. Bayer is buying Chiron Diagnostics in order to get access to its immunoassay, critical care and nucleic acid probe businesses, as well as additional sales and marketing support to help it roll out a plethora of new products in the next year. Chiron is getting out of diagnostics in order to concentrate on pharmaceuticals and doesn't yet know how it will use the money. But Chiron is retaining rights to HCV and to the blood screening business and expects the deal in its entirety to generate $2 billion for it over the next few years.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts